Learn about cystic fibrosis, a genetic disorder that affects the lungs, pancreas, and other organs, and how to treat and live with this chronic disease. 12 min read What Is Cystic Fibrosis? Cystic ...

Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...

The successful use of inhaled morphine to relieve dyspnea in a patient with end-stage cystic fibrosis (CF ... with resulting marked decline in pulmonary function. The only treatment for end ...

Ann & Robert H. Lurie Children's Hospital of Chicago launched a newborn screening awareness campaign, with signage on public transit and billboards across Chicago urging parents to contact their child ...

CONCLUSIONS These data support previous findings that deficiency of α 1-AT is not associated with more severe pulmonary disease in cystic fibrosis and may be associated with milder lung disease.

Ann & Robert H. Lurie Children’s Hospital of Chicago launched a newborn screening awareness campaign, with signage on public transit and billboards across Chicago urging parents to contact their child ...

Chronic airways diseases, including asthma, COPD and cystic fibrosis, cause significant morbidity and mortality and are associated with high healthcare expenditure, in the UK and worldwide. For ...

The Iowa Chapter of the Cystic Fibrosis Foundation welcomes you! Volunteers are the key to our success and the lifeblood of our organization. We have many opportunities for you to get involved. Your ...

In December, the FDA approved Vertex’s vanzacaftor, tezacaftor and deutivacaftor (Alyftrek) for the treatment of cystic fibrosis in patients with at least one F508del mutation or another ...

Background The effect of complex alleles in cystic fibrosis (CF) is poorly defined for the lack of functional studies. Methods We studied 70 homozygous, compound heterozygous or heterozygous for CFTR ...

The authors attribute this to acquisition of cells from a healthy upper lobe site, removed from the lung fibrosis. There are currently no cell based therapies for ... They also offer exploratory data ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in upfront and near-term payments for global rights to an asset that is ...